The Canadian Heart Failure Society is pleased to provide cardiologists with a practical algorithm for the use of SGLT2 inhibitors in the prevention and treatment of cardiomyopathies and cardiovascular diseases. This two-page resource was created by a CHFS committee composed of Dr. Jonathan Howlett (Chair), Dr. Kim Connelly, Dr. Eileen O’Meara and Dr. Shelley Zieroth.
This document was made possible through a sponsorship from AstraZeneca and the Boehringer-Ingelheim – Lilly Alliance.